NCT02501096 2023-07-20A Trial of Lenvatinib (E7080) Plus Pembrolizumab in Participants With Selected Solid TumorsEisai Inc.Phase 1/2 Completed357 enrolled 28 charts 1 FDA
NCT01761266 2022-04-05A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular CarcinomaEisai Inc.Phase 3 Completed954 enrolled 19 charts 1 FDA